FREQライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (4 11月 2023 @ 05:00):

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function...

Stats
本日の出来高	309 164
平均出来高	135 075
時価総額	10.94M
EPS	$0 ( 2024-03-08 )
次の収益日	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.158
ATR14	$0.0510 (17.02%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-27	Meyers Rachel	Buy	12 551	Stock Option (Right to Buy)
2023-11-27	Meyers Rachel	Buy	0
2023-11-22	Lucchino David L.	Sell	110	Common Stock
2023-11-22	Lucchino David L.	Sell	230	Common Stock
2023-11-22	Lucchino David L.	Sell	614	Common Stock

INSIDER POWER
96.44
Last 81 transactions
Buy: 3 077 272 \| Sell: 64 406

ボリューム相関

長: 0.24 (neutral)

短: -0.40 (neutral)

Signal:(51.699) Neutral

Frequency Therapeutics 相関

10 最も正の相関
REVB	0.883
GLPG	0.882
STAF	0.873
GMII	0.873
ZYXI	0.872
SNES	0.871
IMPL	0.867
YQ	0.866
VREX	0.853
TRIT	0.851

10 最も負の相関
SHSP	-0.952
MMAC	-0.944
BNFT	-0.922
EXFO	-0.895
GTYH	-0.89
MNTX	-0.887
ANDA	-0.886
COUP	-0.884
FTNT	-0.868
RMRM	-0.867

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Frequency Therapeutics 相関 - 通貨/商品

-0.43
( neutral )

-0.54
( weak negative )

0.00
( neutral )

-0.44
( neutral )

0.31
( neutral )

0.49
( neutral )

Frequency Therapeutics 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-2.33

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-2.33

FY	2021
収益:	$14 068.00
総利益:	$14 068.00 (100.00 %)
EPS:	$-0.00246

FY	2020
収益:	$36.98M
総利益:	$36.98M (100.00 %)
EPS:	$-0.820

Financial Reports:

No articles found.

Frequency Therapeutics

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.